Optimization of therapeutic procedure during LDL-apheresis - verification of the computerized model in clinical practice

被引:3
|
作者
Masin, Vladimir [1 ]
Blaha, Milan
Stransky, Pravoslav
Blaha, Vladimir
Cermanova, Melanie
Maly, Radovan
Zajic, Jiri
机构
[1] Charles Univ Prague, Fac Med, Hradec Kralove, Czech Republic
[2] Fac Hosp, Hradec Kralove, Czech Republic
关键词
LDL apheresis; familial hypercholesterolemia; atherosclerosis; immunoadsorption;
D O I
10.1016/j.transci.2006.10.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
LDL-apheresis is a very effective method in the treatment of resistant hypercholesterolemia when other therapies fail. To maximize the efficacy of the use of LDL-absorbers, we created a computerized model. The aim of this study is to verify it in clinical use. Patients and methods: A therapeutic technique of immunoadsorption was used, applying a pair of Lipopak columns (Pocard, Russia). Plasma was separated by a continuous-flow plasma separator (Cobe Spectra, USA); adsorption was controlled by adsorption-desorption equipment Adasorb (Medicap, Germany). 494 LDL-apheresis procedures had been performed in nine patients with primary hypercholesterolemia in the earlier, initial study; 47 other procedures (202 therapeutic cycles) were used in this verification study. The program for procedure planning uses Microsoft Excel for Windows. Complex metabolism of the LDL-cholesterol was neglected (owing to the short-time period of the procedure) and the procedure calculated as continuous filtration. The input enterer into the program includes basic patient data (mass, height, sex and initial plasma LDL level in mmol/L). Results: The results show a very good match between calculated levels and the real laboratory results in most procedures, but in some procedures we observed minor differences (0.05 mmol/L), which was caused by procedure adjustments due to technical reasons. However, some methodological and medical details must be carefully observed (initial cholesterol level, correct calculation of plasma volume, and the precise capacity of adsorbers that must not be overshot); as they influence the correct match between calculated and real results significantly. Conclusions: Although our software uses a fairly simplified model of the LDL-cholesterol kinetics during the LDL-apheresis, it is providing a great aid in the procedure planning. It is also suitable for practical use because it only requires a few commonly used and readily available input values. 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:39 / 45
页数:7
相关论文
共 50 条
  • [31] Divide et Vinces, Therapeutic Apheresis in Nephrological Clinical Practice
    Mantilla, Juliana
    Pena, Danna
    Molano-Trivino, Alejandra
    Zuniga, Eduardo
    de la Hoz, Juan Camilo
    BLOOD PURIFICATION, 2024, 53 (03) : 162 - 169
  • [32] Proposal of the Need for New Korean Guidelines on the Use of Therapeutic Apheresis in Clinical Practice
    Chung, Yousun
    Kim, Hyungsuk
    Ko, Dae-Hyun
    ANNALS OF LABORATORY MEDICINE, 2022, 42 (06) : 703 - 707
  • [33] Guidelines on the Use of Therapeutic Apheresis in Clinical Practice Evidence-Based Approach from the Apheresis Applications Committee of the American Society for Apheresis
    Szczepiorkowski, Zbigniew M.
    Winters, Jeffrey L.
    Bandarenko, Nicholas
    Kim, Haewon C.
    Linenberger, Michael L.
    Marques, Marisa B.
    Sarode, Ravindra
    Schwartz, Joseph
    Weinstein, Robert
    Shaz, Beth H.
    JOURNAL OF CLINICAL APHERESIS, 2010, 25 (03) : 83 - 177
  • [34] Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis
    Szczepiorkowski, Zbigniew M.
    Bandarenko, Nicholas
    Kim, Haewon C.
    Linenberger, Michael L.
    Marques, Marisa B.
    Sarode, Ravindra
    Schwartz, Joseph
    Shaz, Beth H.
    Weinstein, Robert
    Wirk, Ashka
    Winters, Jeffrey L.
    JOURNAL OF CLINICAL APHERESIS, 2007, 22 (03) : 106 - 175
  • [35] LDL-apheresis to decrease sFlt-1 during early severe preeclampsia: Report of two cases from a discontinued phase II trial
    Haddad, Bassam
    Lefevre, Guillaume
    Rousseau, Alexandra
    Robert, Thomas
    Saheb, Samir
    Rafat, Cedric
    Bornes, Marie
    Petit-Hoang, Camille
    Richard, Frederic
    Lecarpentier, Edouard
    Tsatsaris, Vassilis
    Guibourdenche, Jean
    Corchia, Anthony
    Rondeau, Eric
    Simon, Tabassome
    Hertig, Alexandre
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2018, 231 : 70 - 74
  • [36] LONG-TERM EFFICIENCY, BIOCOMPATIBILITY, AND CLINICAL SAFETY OF COMBINED SIMULTANEOUS LDL-APHERESIS AND HEMODIALYSIS IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND END-STAGE RENAL-FAILURE
    BOSCH, T
    THIERY, J
    GURLAND, HJ
    SEIDEL, D
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1993, 8 (12) : 1350 - 1358
  • [37] Direct adsorption of lipoproteins (DALI) from whole blood:: First long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolaemia
    Jansen, M
    Banyai, S
    Schmaldienst, S
    Goldammer, A
    Rohac, M
    Hörl, WH
    Derfler, K
    WIENER KLINISCHE WOCHENSCHRIFT, 2000, 112 (02) : 61 - 69
  • [38] IN-111 LABELED AUTOLOGOUS LOW-DENSITY LIPOPROTEINS SHOW LIPID LESION REGRESSION AND UP-REGULATION OF LIVER RECEPTOR DURING LDL-APHERESIS
    SINZINGER, H
    BEDNAR, J
    BLAZEK, I
    GRANEGGER, S
    KARANIKAS, G
    LEITINGER, N
    PIDLICH, J
    CIRCULATION, 1994, 90 (04) : 510 - 510
  • [39] THE HELP-LDL-APHERESIS MULTICENTER STUDY, AN ANGIOGRAPHICALLY ASSESSED TRIAL ON THE ROLE OF LDL-APHERESIS IN THE SECONDARY PREVENTION OF CORONARY HEART-DISEASE .1. EVALUATION OF SAFETY AND CHOLESTEROL-LOWERING EFFECTS DURING THE 1ST 12 MONTHS
    SEIDEL, D
    ARMSTRONG, VW
    SCHUFFWERNER, P
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1991, 21 (04) : 375 - 383
  • [40] Impact of chronic LDL-apheresis treatment on Achilles tendon affection in patients with severe familial hypercholesterolemia:: a clinical and ultrasonographic 3-year follow-up study
    Scheel, AK
    Schettler, V
    Koziolek, M
    Koelling, S
    Werner, C
    Müller, GA
    Strutz, F
    ATHEROSCLEROSIS, 2004, 174 (01) : 133 - 139